Therapeutic nexus of T cell immunometabolism in improving transplantation immunotherapy

Immunometabolism is a therapeutic strategy to tune immune cells through metabolic reprogramming, which allows immune cells to be differentiated according to their energy requirements. Recent therapeutic strategies targeting immunometabolism suggest that intracellular metabolic reprogramming controls T cell activation, proliferation, and differentiation into effector (Teff) or regulatory (Treg) cells. Immunometabolism is being studied for the treatment of inflammatory diseases, including those associated with solid organ transplantation (SOT). Here, we review immunometabolic regulation of immune cells, with a particular focus on Treg metabolic regulation and liver kinase B1 (LKB1) signaling, which stabilize Tregs and prevent inflammation-associated tissue injuries. All in all, here we discussed how targeting T cell immunometabolism modulates Teff and Tregmediated immune responses, which can be used to boost Treg differentiation, stability, and ultimately favor immunotolerance in clinical transplants.

Automated summary

Immunometabolism is a therapeutic strategy that uses metabolic reprogramming to tune immune cells and treat inflammatory diseases, particularly those associated with organ transplantation. This review discusses how targeting T cell immunometabolism can modulate immune cell differentiation and activity, ultimately promoting immunotolerance in clinical transplants.